Lisata Therapeutics, Inc. (LSTA)
USD 1.88
(-5.53%)
USD 1.88
(-5.53%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 25.7 Million USD | -55.37% |
| 2022 | 57.6 Million USD | 98.28% |
| 2021 | 29.05 Million USD | 51.74% |
| 2020 | 19.14 Million USD | -4.71% |
| 2019 | 20.09 Million USD | 18.28% |
| 2018 | 16.98 Million USD | -38.44% |
| 2017 | 27.59 Million USD | -22.24% |
| 2016 | 35.48 Million USD | -34.17% |
| 2015 | 53.9 Million USD | -10.16% |
| 2014 | 60 Million USD | 55.72% |
| 2013 | 38.53 Million USD | 17.59% |
| 2012 | 32.76 Million USD | -7.46% |
| 2011 | 35.4 Million USD | -9.28% |
| 2010 | 39.03 Million USD | 40.51% |
| 2009 | 27.77 Million USD | 199.17% |
| 2008 | 9.28 Million USD | -12.78% |
| 2007 | 10.64 Million USD | 125.8% |
| 2006 | 4.71 Million USD | 192.58% |
| 2005 | 1.61 Million USD | 8.22% |
| 2004 | 1.48 Million USD | 62.67% |
| 2003 | 915.35 Thousand USD | -21.77% |
| 2002 | 1.17 Million USD | -28.78% |
| 2001 | 1.64 Million USD | -39.55% |
| 2000 | 2.71 Million USD | 137.77% |
| 1999 | 1.14 Million USD | 0.0% |
| 1998 | - USD | -100.0% |
| 1997 | 251.58 Thousand USD | -2.14% |
| 1996 | 257.07 Thousand USD | -96.92% |
| 1995 | 8.34 Million USD | 13.01% |
| 1994 | 7.38 Million USD | 2206.25% |
| 1993 | 320 Thousand USD | 0.0% |
| 1990 | 4.57 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.55 Million USD | 9.65% |
| 2024 Q2 | 5.47 Million USD | -15.74% |
| 2023 Q2 | 6.87 Million USD | 0.45% |
| 2023 FY | 25.51 Million USD | -55.7% |
| 2023 Q3 | 5.96 Million USD | -13.25% |
| 2023 Q4 | 5.97 Million USD | 0.23% |
| 2023 Q1 | 6.84 Million USD | 4.65% |
| 2022 Q2 | 6.72 Million USD | 1.51% |
| 2022 Q1 | 6.62 Million USD | -3.34% |
| 2022 FY | 57.6 Million USD | 98.28% |
| 2022 Q4 | 6.54 Million USD | -82.66% |
| 2022 Q3 | 37.72 Million USD | 461.31% |
| 2021 Q2 | 7.14 Million USD | -11.61% |
| 2021 FY | 29.05 Million USD | 51.74% |
| 2021 Q1 | 8.08 Million USD | 48.48% |
| 2021 Q3 | 6.96 Million USD | -2.5% |
| 2021 Q4 | 6.84 Million USD | -1.71% |
| 2020 Q1 | 4.05 Million USD | -20.17% |
| 2020 Q3 | 5.35 Million USD | 24.65% |
| 2020 Q2 | 4.29 Million USD | 5.79% |
| 2020 FY | 19.14 Million USD | -4.71% |
| 2020 Q4 | 5.44 Million USD | 1.79% |
| 2019 Q1 | 4.59 Million USD | 20.96% |
| 2019 FY | 20.09 Million USD | 18.28% |
| 2019 Q4 | 5.08 Million USD | 0.2% |
| 2019 Q3 | 5.07 Million USD | -5.13% |
| 2019 Q2 | 5.34 Million USD | 16.42% |
| 2018 Q4 | 3.79 Million USD | 0.89% |
| 2018 FY | 16.98 Million USD | -38.44% |
| 2018 Q3 | 3.76 Million USD | -11.86% |
| 2018 Q2 | 4.26 Million USD | -17.24% |
| 2018 Q1 | 5.15 Million USD | -29.53% |
| 2017 Q4 | 7.32 Million USD | 19.42% |
| 2017 Q2 | 7.71 Million USD | -18.08% |
| 2017 FY | 27.59 Million USD | -22.24% |
| 2017 Q1 | 9.41 Million USD | 37.44% |
| 2017 Q3 | 6.12 Million USD | -20.5% |
| 2016 Q2 | 8.73 Million USD | -29.19% |
| 2016 FY | 35.48 Million USD | -34.17% |
| 2016 Q1 | 12.33 Million USD | 50.18% |
| 2016 Q3 | 7.56 Million USD | -13.36% |
| 2016 Q4 | 6.84 Million USD | -9.5% |
| 2015 Q1 | 17.89 Million USD | 7.35% |
| 2015 FY | 53.9 Million USD | -10.16% |
| 2015 Q3 | 11.46 Million USD | -29.84% |
| 2015 Q4 | 8.21 Million USD | -28.35% |
| 2015 Q2 | 16.33 Million USD | -8.69% |
| 2014 Q3 | 16.36 Million USD | 23.58% |
| 2014 Q1 | 13.72 Million USD | 22.27% |
| 2014 Q4 | 16.66 Million USD | 1.85% |
| 2014 FY | 60 Million USD | 55.72% |
| 2014 Q2 | 13.24 Million USD | -3.55% |
| 2013 Q1 | 8.96 Million USD | 9.52% |
| 2013 Q4 | 11.22 Million USD | 11.8% |
| 2013 Q3 | 10.04 Million USD | 21.09% |
| 2013 Q2 | 8.29 Million USD | -7.46% |
| 2013 FY | 38.53 Million USD | 17.59% |
| 2012 Q4 | 8.18 Million USD | -6.74% |
| 2012 Q1 | 12.16 Million USD | -8.2% |
| 2012 Q2 | 7.44 Million USD | -38.79% |
| 2012 Q3 | 8.77 Million USD | 17.83% |
| 2012 FY | 32.76 Million USD | -7.46% |
| 2011 Q3 | 11.29 Million USD | -24.5% |
| 2011 Q2 | 14.96 Million USD | 12.17% |
| 2011 FY | 35.4 Million USD | -9.28% |
| 2011 Q4 | 13.25 Million USD | 17.33% |
| 2011 Q1 | 13.33 Million USD | 27.33% |
| 2010 FY | 39.03 Million USD | 40.51% |
| 2010 Q1 | 7.58 Million USD | -45.67% |
| 2010 Q2 | 9.99 Million USD | 31.74% |
| 2010 Q4 | 10.47 Million USD | -4.65% |
| 2010 Q3 | 10.98 Million USD | 9.88% |
| 2009 Q2 | 4.71 Million USD | 151.0% |
| 2009 Q4 | 13.96 Million USD | 92.32% |
| 2009 Q3 | 7.26 Million USD | 54.04% |
| 2009 FY | 27.77 Million USD | 199.17% |
| 2009 Q1 | 1.87 Million USD | -23.19% |
| 2008 FY | 9.28 Million USD | -12.78% |
| 2008 Q4 | 2.44 Million USD | 26.34% |
| 2008 Q3 | 1.93 Million USD | -18.65% |
| 2008 Q2 | 2.37 Million USD | -5.74% |
| 2008 Q1 | 2.52 Million USD | 1.69% |
| 2007 Q1 | 1.87 Million USD | 7.91% |
| 2007 FY | 10.64 Million USD | 125.8% |
| 2007 Q3 | 4.32 Million USD | 120.75% |
| 2007 Q4 | 2.48 Million USD | -42.64% |
| 2007 Q2 | 1.96 Million USD | 4.66% |
| 2006 Q2 | 1.03 Million USD | 10.67% |
| 2006 FY | 4.71 Million USD | 192.58% |
| 2006 Q3 | 999.82 Thousand USD | -3.81% |
| 2006 Q4 | 1.73 Million USD | 73.61% |
| 2006 Q1 | 939.23 Thousand USD | 90.7% |
| 2005 Q2 | 358.76 Thousand USD | 66.48% |
| 2005 Q1 | 215.5 Thousand USD | -18.97% |
| 2005 Q3 | 544.61 Thousand USD | 51.8% |
| 2005 Q4 | 492.52 Thousand USD | -9.56% |
| 2005 FY | 1.61 Million USD | 8.22% |
| 2004 Q1 | 389.08 Thousand USD | 3.47% |
| 2004 Q2 | 415.53 Thousand USD | 6.8% |
| 2004 Q3 | 418.4 Thousand USD | 0.69% |
| 2004 Q4 | 265.95 Thousand USD | -36.44% |
| 2004 FY | 1.48 Million USD | 62.67% |
| 2003 Q4 | 376.03 Thousand USD | 86.85% |
| 2003 Q3 | 201.25 Thousand USD | -3.93% |
| 2003 FY | 915.35 Thousand USD | -21.77% |
| 2003 Q2 | 209.49 Thousand USD | 62.93% |
| 2003 Q1 | 128.57 Thousand USD | -64.51% |
| 2002 Q1 | 371.43 Thousand USD | -21.64% |
| 2002 FY | 1.17 Million USD | -28.78% |
| 2002 Q4 | 362.32 Thousand USD | 57.01% |
| 2002 Q3 | 230.77 Thousand USD | 12.28% |
| 2002 Q2 | 205.52 Thousand USD | -44.67% |
| 2001 Q2 | 359.31 Thousand USD | -14.89% |
| 2001 Q4 | 474.02 Thousand USD | 22.37% |
| 2001 Q3 | 387.36 Thousand USD | 7.81% |
| 2001 Q1 | 422.17 Thousand USD | -45.26% |
| 2001 FY | 1.64 Million USD | -39.55% |
| 2000 FY | 2.71 Million USD | 137.77% |
| 2000 Q3 | 1.04 Million USD | 95.47% |
| 2000 Q2 | 535.03 Thousand USD | 46.36% |
| 2000 Q1 | 365.56 Thousand USD | 198.8% |
| 2000 Q4 | 771.27 Thousand USD | -26.25% |
| 1999 Q1 | 400 Thousand USD | 0.0% |
| 1999 Q4 | -370 Thousand USD | -186.05% |
| 1999 Q3 | 430 Thousand USD | -28.33% |
| 1999 Q2 | 600 Thousand USD | 50.0% |
| 1999 FY | 1.14 Million USD | 0.0% |
| 1998 FY | - USD | -100.0% |
| 1997 Q1 | 140 Thousand USD | 180.0% |
| 1997 FY | 251.58 Thousand USD | -2.14% |
| 1996 Q3 | 40 Thousand USD | 33.33% |
| 1996 Q2 | 30 Thousand USD | 100.19% |
| 1996 Q1 | -15.39 Million USD | -510.4% |
| 1996 Q4 | 50 Thousand USD | 25.0% |
| 1996 FY | 257.07 Thousand USD | -96.92% |
| 1995 FY | 8.34 Million USD | 13.01% |
| 1995 Q2 | 6.4 Million USD | -4.05% |
| 1995 Q4 | 3.75 Million USD | -31.69% |
| 1995 Q3 | 5.49 Million USD | -14.22% |
| 1995 Q1 | 6.67 Million USD | 17.02% |
| 1994 Q4 | 5.7 Million USD | -22.66% |
| 1994 Q3 | 7.37 Million USD | 78.02% |
| 1994 FY | 7.38 Million USD | 2206.25% |
| 1994 Q2 | 4.14 Million USD | 0.0% |
| 1993 FY | 320 Thousand USD | 0.0% |
| 1990 FY | 4.57 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 90.66% |
| Alkermes plc | 996.24 Million USD | 97.42% |
| Agenus Inc. | 78.18 Million USD | 67.118% |
| Aptorum Group Limited | 10.56 Thousand USD | -243208.726% |
| Ardelyx, Inc. | 169.93 Million USD | 84.872% |
| Dyadic International, Inc. | 9.15 Million USD | -180.879% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -15.526% |
| Lantern Pharma Inc. | 17.87 Million USD | -43.8% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -281.881% |
| Novavax, Inc. | 779.12 Million USD | 96.7% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 68.286% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 68.724% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -32.389% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 13.166% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 51.61% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 93.244% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -5.765% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 32.113% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 16.454% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 69.654% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -47.265% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 84.737% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 21.418% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 83.911% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 98.572% |
| AlloVir, Inc. | 180.93 Million USD | 85.791% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 94.232% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 13.389% |
| Bicycle Therapeutics plc | 216.92 Million USD | 88.149% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 85.045% |
| ChromaDex Corporation | 56.37 Million USD | 54.401% |
| Chimerix, Inc. | 93.38 Million USD | 72.472% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -84.821% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 82.922% |
| CRISPR Therapeutics AG | 463.49 Million USD | 94.453% |
| Precision BioSciences, Inc. | 92.46 Million USD | 72.196% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 89.88% |
| Fortress Biotech, Inc. | 200.19 Million USD | 87.159% |
| Fortress Biotech, Inc. | 200.19 Million USD | 87.159% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 21.493% |
| ImmuCell Corporation | 9.61 Million USD | -167.308% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 83.71% |
| Immix Biopharma, Inc. | 16.14 Million USD | -59.27% |
| Incyte Corporation | 1.19 Billion USD | 97.841% |
| Innoviva, Inc. | 132.15 Million USD | 80.547% |
| IO Biotech, Inc. | 91.44 Million USD | 71.886% |
| Jaguar Health, Inc. | 42.01 Million USD | 38.812% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 84.813% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 69.512% |
| ContextLogic Inc. | 387 Million USD | 93.357% |
| MiMedx Group, Inc. | 229.72 Million USD | 88.809% |
| MEI Pharma, Inc. | 34.78 Million USD | 26.095% |
| NextCure, Inc. | 67.63 Million USD | 61.991% |
| Onconetix, Inc. | 34.9 Million USD | 26.354% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -101.695% |
| Opthea Limited | 191.96 Million USD | 86.608% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -834.298% |
| Vaxcyte, Inc. | 468.04 Million USD | 94.507% |
| PDS Biotechnology Corporation | 43.04 Million USD | 40.277% |
| Precigen, Inc. | 84.18 Million USD | 69.461% |
| Pharming Group N.V. | 225.49 Million USD | 88.599% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 84.682% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 64.573% |
| PureTech Health plc | 144.59 Million USD | 82.221% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 80.265% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 89.514% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -5.765% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 88.758% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 16.692% |
| Acelyrin, Inc. | 422.06 Million USD | 93.909% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -199279.556% |
| Summit Therapeutics Inc. | 87.68 Million USD | 70.682% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 30.639% |
| Senti Biosciences, Inc. | 94.7 Million USD | 72.855% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 79.193% |
| Elevation Oncology, Inc. | 45.44 Million USD | 43.431% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 12.763% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -552.148% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 80.55% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 24.577% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -204.201% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 85.82% |
| Seer, Inc. | 110.49 Million USD | 76.733% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 63.583% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 72.498% |
| ESSA Pharma Inc. | 32.13 Million USD | 19.998% |
| GlycoMimetics, Inc. | 39.28 Million USD | 34.561% |
| GT Biopharma, Inc. | 13.57 Million USD | -89.364% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 88.306% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 87.217% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 90.09% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 54.707% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 52.463% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -158.693% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 93.63% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -35.813% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 49.287% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 90.099% |
| Aptose Biosciences Inc. | 52.35 Million USD | 50.898% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -78.399% |
| Soligenix, Inc. | 7.79 Million USD | -229.791% |
| Century Therapeutics, Inc. | 56.07 Million USD | 54.151% |
| Kura Oncology, Inc. | 165.8 Million USD | 84.495% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 77.549% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -209.028% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -935.928% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 76.13% |
| Autolus Therapeutics plc | 196.72 Million USD | 86.932% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 69.633% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 77.924% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -32.632% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 92.01% |
| GRI Bio, Inc. | 11.33 Million USD | -126.902% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -264.358% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 80.404% |
| IGM Biosciences, Inc. | 265.59 Million USD | 90.32% |
| INmune Bio, Inc. | 29.89 Million USD | 14.009% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 85.101% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 36.231% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -60.883% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -63.313% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 58.601% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 76.09% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 90.675% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 91.472% |
| Verastem, Inc. | 92.08 Million USD | 72.082% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -43.308% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 86.158% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 78.825% |
| Histogen Inc. | 14.27 Million USD | -80.129% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -60.193% |
| Surrozen, Inc. | 18.55 Million USD | -38.588% |
| Organovo Holdings, Inc. | 14.91 Million USD | -72.363% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -405.045% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 56.919% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -0.238% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 45.309% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -236.808% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 85.568% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 46.937% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 89.507% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -67.298% |
| Apollomics, Inc. | 54.14 Million USD | 52.516% |
| Amarin Corporation plc | 272.35 Million USD | 90.561% |
| Mesoblast Limited | 5.9 Million USD | -335.581% |
| Turnstone Biologics Corp. | 78.33 Million USD | 67.183% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 89.469% |
| Synaptogenix, Inc. | 8.31 Million USD | -209.219% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -76.251% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 89.841% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 22.868% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -191.103% |
| Exelixis, Inc. | 1.58 Billion USD | 98.38% |
| Better Therapeutics, Inc. | 38.26 Million USD | 32.811% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 88.921% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 96.994% |
| NLS Pharmaceutics AG | 11.8 Million USD | -117.734% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -219.675% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 14.287% |
| Gritstone bio, Inc. | 148.37 Million USD | 82.674% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 62.667% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -57.137% |
| Avid Bioservices, Inc. | 25.99 Million USD | 1.108% |
| Insmed Incorporated | 949.26 Million USD | 97.292% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -63.852% |
| MediWound Ltd. | 18.86 Million USD | -36.252% |
| OmniAb, Inc. | 83.89 Million USD | 69.357% |
| Alector, Inc. | 248.8 Million USD | 89.667% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 89.028% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 50.799% |
| Zai Lab Limited | 547.47 Million USD | 95.304% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 93.551% |
| Aura Biosciences, Inc. | 84.99 Million USD | 69.752% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 89.598% |
| Immunic, Inc. | 99.22 Million USD | 74.091% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 83.833% |
| Veracyte, Inc. | 357.93 Million USD | 92.818% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.715% |
| FibroGen, Inc. | 398.11 Million USD | 93.543% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -80.915% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -273.232% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -260.777% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.21% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 0.638% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 91.879% |
| TG Therapeutics, Inc. | 198.47 Million USD | 87.047% |
| Galecto, Inc. | 35.62 Million USD | 27.841% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 36.818% |
| Fortrea Holdings Inc. | 457.3 Million USD | 94.378% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 52.636% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 10.977% |
| XBiotech Inc. | 37.51 Million USD | 31.464% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 62.667% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -24.5% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 81.904% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 74.052% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 76.78% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 97.317% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 10.875% |
| Vaxxinity, Inc. | 56.05 Million USD | 54.135% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 94.03% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -15.24% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 76.812% |
| NexImmune, Inc. | 28.16 Million USD | 8.732% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -364.803% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -43.68% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.087% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -0.978% |
| Scopus BioPharma Inc. | 11.71 Million USD | -119.447% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 79.767% |
| Ainos, Inc. | 12.95 Million USD | -98.477% |
| Pluri Inc. | 22.48 Million USD | -14.359% |
| Prothena Corporation plc | 282.4 Million USD | 90.897% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 87.147% |
| Celularity Inc. | 215.05 Million USD | 88.046% |
| Rallybio Corporation | 78.93 Million USD | 67.43% |
| Cue Biopharma, Inc. | 19.54 Million USD | -31.553% |
| MeiraGTx Holdings plc | 151.07 Million USD | 82.984% |
| Omeros Corporation | 94.75 Million USD | 72.868% |
| Humacyte, Inc. | 23.49 Million USD | -9.41% |
| Immunocore Holdings plc | 308.04 Million USD | 91.654% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -658.348% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 70.405% |
| Blueprint Medicines Corporation | 722.86 Million USD | 96.444% |
| CalciMedica, Inc. | 21.81 Million USD | -17.835% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 65.567% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 83.987% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 84.992% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 91.284% |
| Pulmatrix, Inc. | 22.03 Million USD | -16.653% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 25.646% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 71.071% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 95.339% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 64.566% |
| Cytokinetics, Incorporated | 173.61 Million USD | 85.192% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 25.309% |
| Nutriband Inc. | 5.73 Million USD | -348.341% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 41.054% |
| Vor Biopharma Inc. | 126.03 Million USD | 79.603% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 97.838% |
| Evogene Ltd. | 27.79 Million USD | 7.492% |
| ProKidney Corp. | 151.52 Million USD | 83.033% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 65.341% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -234.207% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 95.815% |
| CorMedix Inc. | 48.95 Million USD | 47.489% |
| BioLineRx Ltd. | 50.8 Million USD | 49.396% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 82.941% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 32.475% |
| Atai Life Sciences N.V. | 125.78 Million USD | 79.562% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 68.51% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 68.421% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 89.821% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 21.478% |
| MediciNova, Inc. | 10.9 Million USD | -135.847% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 80.043% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -254.128% |
| GeoVax Labs, Inc. | 6.02 Million USD | -326.889% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 94.603% |
| Biomea Fusion, Inc. | 126.13 Million USD | 79.619% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 98.04% |
| Mereo BioPharma Group plc | 35.84 Million USD | 28.274% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 86.547% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 88.82% |
| Absci Corporation | 73.66 Million USD | 65.102% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 6.794% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 80.756% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 89.384% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 90.19% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 87.64% |
| Allakos Inc. | 196.05 Million USD | 86.887% |
| Imunon, Inc. | 20.31 Million USD | -26.575% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 77.344% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 93.026% |
| BioAtla, Inc. | 129.68 Million USD | 80.177% |
| NLS Pharmaceutics AG | 11.8 Million USD | -117.734% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -62.267% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 69.726% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 38.436% |
| XOMA Corporation | 46.46 Million USD | 44.67% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 76.875% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 81.955% |
| aTyr Pharma, Inc. | 12.97 Million USD | -98.074% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 75.199% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 85.129% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 89.909% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 31.277% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -212.566% |
| Akari Therapeutics, Plc | 16.8 Million USD | -52.969% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -1030.534% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 91.411% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -282.063% |
| UroGen Pharma Ltd. | 138.88 Million USD | 81.49% |
| Sutro Biopharma, Inc. | 243 Million USD | 89.421% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -253.393% |
| Orgenesis Inc. | 45.75 Million USD | 43.816% |
| Entera Bio Ltd. | 8.86 Million USD | -190.158% |
| GH Research PLC | 41.22 Million USD | 37.635% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 69.046% |
| Xencor, Inc. | 306.97 Million USD | 91.625% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -421.079% |
| Replimune Group, Inc. | 234.77 Million USD | 89.05% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -25.467% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 86.596% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -282.063% |
| Portage Biotech Inc. | 18.19 Million USD | -41.261% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -254.128% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 75.507% |
| OncoCyte Corporation | 25.63 Million USD | -0.277% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -321.746% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -124.386% |
| Purple Biotech Ltd. | -22.46 Million USD | 214.426% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -55.995% |
| scPharmaceuticals Inc. | 65.17 Million USD | 60.557% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -204.138% |
| HilleVax, Inc. | 133.34 Million USD | 80.721% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -149.956% |
| Tharimmune, Inc. | 9.45 Million USD | -171.892% |
| Genprex, Inc. | 31.06 Million USD | 17.233% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 86.291% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 18.067% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -3260.523% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -371.973% |
| OKYO Pharma Limited | 8243.57 USD | -311755.179% |
| Savara Inc. | 15.74 Million USD | -63.277% |
| Curis, Inc. | 58.35 Million USD | 55.946% |
| Daré Bioscience, Inc. | 33.6 Million USD | 23.509% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -404.822% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -244.565% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 4.863% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.218% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -28.931% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 94.846% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 83.269% |
| Erasca, Inc. | 141.52 Million USD | 81.835% |
| bluebird bio, Inc. | 240.23 Million USD | 89.299% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -467.885% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 98.528% |
| DBV Technologies S.A. | 92.16 Million USD | 72.105% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -467.885% |
| Moderna, Inc. | 6.39 Billion USD | 99.598% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 39.665% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -78.95% |
| Molecular Templates, Inc. | 63.09 Million USD | 59.253% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 61.458% |
| Travere Therapeutics, Inc. | 472 Million USD | 94.553% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 82.061% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 58.59% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 40.784% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 87.648% |
| MacroGenics, Inc. | 217.21 Million USD | 88.165% |
| RenovoRx, Inc. | 11.39 Million USD | -125.588% |
| Adicet Bio, Inc. | 152.03 Million USD | 83.091% |
| Prime Medicine, Inc. | 186.63 Million USD | 86.226% |
| Aditxt, Inc. | 25.95 Million USD | 0.935% |
| Adagene Inc. | 41.83 Million USD | 38.544% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -251.678% |
| Quantum-Si incorporated | 111.65 Million USD | 76.976% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 85.04% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -76.351% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 28.234% |
| SciSparc Ltd. | 9.01 Million USD | -185.296% |
| Vericel Corporation | 142.04 Million USD | 81.901% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -196.974% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -11.345% |
| Generation Bio Co. | 144.46 Million USD | 82.205% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 69.038% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 70.266% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 91.307% |
| Invivyd, Inc. | 205.75 Million USD | 87.506% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 64.373% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -174.116% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 65.838% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -149.908% |
| 2seventy bio, Inc. | 289.88 Million USD | 91.132% |
| ADMA Biologics, Inc. | 66.58 Million USD | 61.391% |
| Clene Inc. | 41.07 Million USD | 37.409% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -100.72% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 53.084% |
| GeoVax Labs, Inc. | 6.02 Million USD | -326.889% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 92.698% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 30.012% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 23.778% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 75.21% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 21.114% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 84.902% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 96.651% |
| Evaxion Biotech A/S | 22.27 Million USD | -15.438% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 81.033% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 89.055% |
| Trevena, Inc. | 38.41 Million USD | 33.075% |
| Surrozen, Inc. | 18.55 Million USD | -38.588% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 67.843% |
| Cingulate Inc. | 22.75 Million USD | -12.957% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 443.139% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 42.445% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -212.22% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 74.933% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 96.591% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 58.585% |
| Clearmind Medicine Inc. | 8.74 Million USD | -194.096% |
| Kronos Bio, Inc. | 128.11 Million USD | 79.934% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 69.421% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -776.513% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 74.503% |
| Statera Biopharma, Inc. | 28.82 Million USD | 10.827% |
| ImmunityBio, Inc. | 362.87 Million USD | 92.915% |
| Korro Bio, Inc. | 84.53 Million USD | 69.589% |
| Kineta, Inc. | 21.15 Million USD | -21.516% |
| BioVie Inc. | 31.95 Million USD | 19.537% |
| Codexis, Inc. | 66.51 Million USD | 61.352% |
| Celularity Inc. | 215.05 Million USD | 88.046% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 88.656% |
| Celcuity Inc. | 66.23 Million USD | 61.184% |
| Virax Biolabs Group Limited | 6.54 Million USD | -292.665% |
| Cibus, Inc. | 320.3 Million USD | 91.974% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 40.214% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 24.04% |
| IN8bio, Inc. | 30.33 Million USD | 15.259% |
| Kodiak Sciences Inc. | 277.32 Million USD | 90.73% |
| Annexon, Inc. | 143.72 Million USD | 82.113% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 79.851% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -12.218% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -3916.875% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 96.702% |
| Eyenovia, Inc. | 25.4 Million USD | -1.187% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 81.678% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -362.208% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 67.513% |
| Arcellx, Inc. | 200.19 Million USD | 87.159% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 43.991% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 88.121% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -158.19% |
| Moolec Science SA | 52.75 Million USD | 51.265% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 57.951% |
| Geron Corporation | 70.44 Million USD | 63.504% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 44.761% |
| Royalty Pharma plc | 862.4 Million USD | 97.019% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 72.672% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -175.604% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -13.609% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 87.629% |
| Humacyte, Inc. | 23.49 Million USD | -9.41% |
| Structure Therapeutics Inc. | 102.77 Million USD | 74.986% |
| 89bio, Inc. | 151.2 Million USD | 82.998% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 67.918% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -76.809% |
| Genelux Corporation | 24.33 Million USD | -5.642% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 24.217% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 85.129% |
| Notable Labs, Ltd. | 14.77 Million USD | -74.056% |
| Liquidia Corporation | 87.98 Million USD | 70.781% |
| Mustang Bio, Inc. | 48.5 Million USD | 46.995% |
| Immunovant, Inc. | 282.7 Million USD | 90.907% |
| Quantum-Si incorporated | 111.65 Million USD | 76.976% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -14.035% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -20.882% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 74.799% |
| Acasti Pharma Inc. | 11.3 Million USD | -127.484% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -12.159% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -60.883% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 44.764% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -2165.86% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -61.828% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 11.829% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 37.879% |
| PepGen Inc. | 84.76 Million USD | 69.672% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 13.24% |
| United Therapeutics Corporation | 885.1 Million USD | 97.095% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -12.277% |
| Solid Biosciences Inc. | 104.31 Million USD | 75.355% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 21.444% |
| Immuneering Corporation | 58.41 Million USD | 55.989% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -405.045% |
| Silo Pharma, Inc. | 3.92 Million USD | -555.506% |
| Belite Bio, Inc | 31.66 Million USD | 18.82% |
| XOMA Corporation | 46.46 Million USD | 44.67% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 61.942% |
| Bionomics Limited | 17.89 Billion USD | 99.856% |
| Apogee Therapeutics, Inc. | 93 Million USD | 72.358% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 172.052% |
| uniQure N.V. | 285.08 Million USD | 90.982% |
| Cassava Sciences, Inc. | 105.95 Million USD | 75.737% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -251.678% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 86.763% |
| Forte Biosciences, Inc. | 32.47 Million USD | 20.842% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -209.409% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 12.543% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -362.208% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -80.915% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -189.211% |
| Altimmune, Inc. | 30.55 Million USD | 15.866% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 93.989% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 172.052% |
| Compugen Ltd. | 43.97 Million USD | 41.534% |
| Peak Bio, Inc. | 1249.13 USD | -2057972.418% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 65.316% |
| Benitec Biopharma Inc. | 22.38 Million USD | -14.86% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 89.429% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 9.932% |
| Zura Bio Limited | 62.63 Million USD | 58.958% |
| PolyPid Ltd. | 21.04 Million USD | -22.157% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -57.95% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 9.932% |
| Instil Bio, Inc. | 85.78 Million USD | 70.032% |
| argenx SE | 1.53 Billion USD | 98.324% |
| Immunome, Inc. | 122.82 Million USD | 79.069% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 46.964% |
| Verona Pharma plc | 67.15 Million USD | 61.716% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 0.684% |
| Shattuck Labs, Inc. | 93.61 Million USD | 72.538% |
| CervoMed Inc. | 14.95 Million USD | -71.871% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 63.639% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -200.89% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 49.592% |
| Moolec Science SA | 52.75 Million USD | 51.265% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -56.294% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 80.606% |
| AnaptysBio, Inc. | 181.56 Million USD | 85.841% |
| Design Therapeutics, Inc. | 78.19 Million USD | 67.121% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 70.464% |
| NeurAxis, Inc. | 8.82 Million USD | -191.434% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -104.275% |
| Lumos Pharma, Inc. | 38.66 Million USD | 33.511% |
| Achilles Therapeutics plc | 75.25 Million USD | 65.839% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 0.684% |
| 180 Life Sciences Corp. | 13.47 Million USD | -90.748% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 2.998% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -776.513% |
| Nutriband Inc. | 5.73 Million USD | -348.341% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 76.794% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 53.807% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 49.472% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 61.107% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 52.501% |
| Palisade Bio, Inc. | 13.32 Million USD | -93.003% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 43.386% |
| Beam Therapeutics Inc. | 554.19 Million USD | 95.361% |
| Neurogene Inc. | 55.58 Million USD | 53.748% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 89.654% |
| AEON Biopharma, Inc. | 48.42 Million USD | 46.916% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 73.417% |
| Sesen Bio, Inc. | 78.38 Million USD | 67.201% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 69.223% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -104.244% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 94.3% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 70.75% |
| Athira Pharma, Inc. | 125.46 Million USD | 79.51% |
| Vaccinex, Inc. | 23.45 Million USD | -9.606% |
| HCW Biologics Inc. | 21.02 Million USD | -22.259% |
| XOMA Corporation | 46.46 Million USD | 44.67% |
| Nektar Therapeutics | 190.9 Million USD | 86.533% |
| Arvinas, Inc. | 480 Million USD | 94.644% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -1030.534% |
| Merus N.V. | 200.49 Million USD | 87.178% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 75.127% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 25.742% |
| Rezolute, Inc. | 70.38 Million USD | 63.476% |
| Clene Inc. | 41.07 Million USD | 37.409% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -56.962% |
| BeyondSpring Inc. | 24.86 Million USD | -3.39% |
| Synlogic, Inc. | 58.53 Million USD | 56.079% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -43.684% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -472.306% |
| Peak Bio, Inc. | 1249.13 USD | -2057972.418% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 57.469% |
| Krystal Biotech, Inc. | 160.42 Million USD | 83.975% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 90.501% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 92.613% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -1091.988% |
| MannKind Corporation | 125.59 Million USD | 79.531% |
| Ikena Oncology, Inc. | 84.57 Million USD | 69.604% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -166.487% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 71.308% |
| Gossamer Bio, Inc. | 183.75 Million USD | 86.01% |
| CohBar, Inc. | 12.38 Million USD | -107.518% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 49.318% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 6.794% |
| Legend Biotech Corporation | 583.14 Million USD | 95.591% |
| Mural Oncology plc | 192.07 Million USD | 86.615% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 61.714% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -59.229% |
| Disc Medicine, Inc. | 91.12 Million USD | 71.788% |
| Champions Oncology, Inc. | 28.11 Million USD | 8.545% |
| REGENXBIO Inc. | 321.15 Million USD | 91.995% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -379.516% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 53.892% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 34.015% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 77.52% |
| Vaxart, Inc. | 90.72 Million USD | 71.664% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -201.737% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 39.926% |
| Cellectis S.A. | 97.32 Million USD | 73.584% |
| Longeveron Inc. | 21.25 Million USD | -20.979% |
| Repare Therapeutics Inc. | 167.35 Million USD | 84.639% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 98.111% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 66.015% |
| Revolution Medicines, Inc. | 498.76 Million USD | 94.846% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -286.47% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 41.512% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 65.534% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 63.082% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -132.441% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.462% |
| Denali Therapeutics Inc. | 527.23 Million USD | 95.124% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -196.974% |
| Veru Inc. | 101.34 Million USD | 74.634% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -9.83% |
| Cingulate Inc. | 22.75 Million USD | -12.957% |
| Passage Bio, Inc. | 108.38 Million USD | 76.282% |
| Context Therapeutics Inc. | 25.07 Million USD | -2.534% |
| Exicure, Inc. | 14.07 Million USD | -82.637% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 87.524% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 40.63% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -180.126% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 89.818% |
| Nuvalent, Inc. | 149.49 Million USD | 82.803% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -218.685% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 75.197% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -19.856% |
| OmniAb, Inc. | 83.89 Million USD | 69.357% |
| Anew Medical, Inc. | 1.3 Million USD | -1876.26% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 21.536% |
| Lipocine Inc. | 15.08 Million USD | -70.476% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 62.477% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 66.241% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 36.231% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 77.615% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -14.85% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 96.129% |
| Ocugen, Inc. | 71.56 Million USD | 64.078% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 72.612% |
| Q32 Bio Inc. | 92.68 Million USD | 72.262% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -21.413% |
| Alumis Inc. Common Stock | 158.17 Million USD | 83.747% |
| Equillium, Inc. | 50.6 Million USD | 49.2% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 58.805% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -84.876% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -36.273% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 45.245% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 76.299% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -107.444% |
| Dominari Holdings Inc. | 23.83 Million USD | -7.858% |
| Edesa Biotech, Inc. | 9.22 Million USD | -178.745% |
| vTv Therapeutics Inc. | 11.9 Million USD | -115.907% |
| Bio-Techne Corporation | 563.03 Million USD | 95.434% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 93.711% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 90.434% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 80.565% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -78.392% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 84.295% |
| Nkarta, Inc. | 131.65 Million USD | 80.472% |
| BioCardia, Inc. | 12.12 Million USD | -112.095% |
| Iterum Therapeutics plc | 47.46 Million USD | 45.841% |